Effect of age and disease on the pharmacokinetics of XXXX .

@entity1 @entity8 @entity99 @entity177 @entity6845 @entity71363 @entity9695
@entity9695 is a nonsteroidal anti-inflammatory agent with additional antipyretic and analgesic activity. The recommended dosage is 100 to 200 mg twice daily orally or rectally. The pharmacokinetics profile of @entity9695 has been studied in @entity1 with a predisposition for altered pharmacokinetics. The pharmacokinetic profile of @entity9695 and its hydroxy metabolite was not altered when the drug was administered in a standard regimen (100mg twice daily) to elderly @entity1 aged < 80 years, suggesting that dosage adjustment is not necessary for such @entity1 . In @entity1 aged 7 to 9 years, @entity9695 50mg administered in a granular formulation showed a tendency for greater absorption and elimination than that recorded for adults administered @entity9695 in tablet form. These results suggest that the pharmacokinetic profile of this paediatric formulation should be assessed in @entity1 aged < 7 years to determine whether their dosage should be adjusted. In @entity1 with moderate @entity177 , the pharmacokinetic profile of @entity9695 was not altered even though the terminal elimination half-life of its @entity6845 metabolite was greater and this resulted in slight accumulation with multiple dose administration in a standard regimen. This slight effect was not considered to be clinically significant and therefore dosage adjustment for @entity1 with moderate @entity8 appears unnecessary. Administration of @entity9695 to @entity1 with severe @entity177 should be avoided until the propensity and significance of @entity71363 accumulation is quantified in this @entity1 group. The pharmacokinetic profile of @entity9695 has not been determined in @entity1 with @entity99 .(ABSTRACT TRUNCATED AT 250 WORDS)
